title: Preparation and In vitro Evaluation of Naproxen Suppositories.
abstract: The aim of this work was to develop the best formulations for naproxen suppositories. The effects of different bases and surfactants on the physicochemical characteristics of the suppositories were determined by several tests such as weight variation, melting point, assay, hardness, and release rate. All formulations met the standard criteria for tested physicochemical parameters; weight variation (97-112%), content uniformity (97-105%), melting point (4.66-8.7 min) and hardness tests (>5400 g). Based on release rate studies, hydrophilic, and lipophilic bases without surfactants were not suitable bases for naproxen suppository. Amongst the formulations containing surfactants only Witepsol H15 with 0.5% w/w of Tween 80 and Witepsol W35 with 0.5% of cetylpyridinium chloride were suitable and released nearly complete drug during 30 and 60 min, respectively. This study demonstrates the effects of incorporation of known agents on the in vitro release characteristics of naproxen suppository.
authors.affiliation: Zahravi Pharmaceutical Company, Sorom Darou Street, 19 km Tehran Road, Tabriz, Iran.
authors.forename: S
authors.initials: S
authors.lastname: Hargoli
authors.forename: J
authors.initials: J
authors.lastname: Farid
authors.forename: S H
authors.initials: SH
authors.lastname: Azarmi
authors.forename: S
authors.initials: S
authors.lastname: Ghanbarzadeh
authors.forename: P
authors.initials: P
authors.lastname: Zakeri-Milani
keywords: Naproxen; Witepsol; polyethylene glycols; suppository; surfactant
references.citation: Int J Pharm. 2004 Jul 26;279(1-2):3-7
references.pmid: 15234788
references.citation: Eur J Pharm Sci. 2003 Jun;19(2-3):123-8
references.pmid: 12791414
references.citation: Int J Pharm. 1999 Nov 5;189(2):137-45
references.pmid: 10536242
references.citation: Eur J Pharm Biopharm. 2002 May;53(3):311-5
references.pmid: 11976019
references.citation: J Control Release. 1999 May 20;59(2):163-72
references.pmid: 10332051
references.citation: J Control Release. 2004 Sep 14;99(1):63-71
references.pmid: 15342181
references.citation: Int J Gynaecol Obstet. 2008 Jul;102(1):19-22
references.pmid: 18321517
references.citation: Eur J Pharm Biopharm. 2001 Sep;52(2):249-54
references.pmid: 11522493
references.citation: Chem Pharm Bull (Tokyo). 1987 Mar;35(3):1201-6
references.pmid: 3607943
references.citation: Acta Med Okayama. 1991 Feb;45(1):37-42
references.pmid: 2063694
references.citation: J Chromatogr A. 2001 Jul 27;924(1-2):459-64
references.pmid: 11521897
references.citation: Talanta. 1999 Sep 13;50(2):401-7
references.pmid: 18967730
references.citation: Int J Pharm. 1999 Nov 5;189(2):147-60
references.pmid: 10536243
references.citation: Biol Pharm Bull. 2006 Feb;29(2):330-5
references.pmid: 16462041
references.citation: Acta Med Okayama. 1992 Aug;46(4):223-31
references.pmid: 1442146
references.citation: Int J Pharm. 2004 Jul 8;278(2):275-82
references.pmid: 15196632
references.citation: Adv Drug Deliv Rev. 1999 Mar 1;36(1):81-99
references.pmid: 10837710
references.citation: Farmaco. 2003 Jul;58(7):509-12
references.pmid: 12818689
references.citation: Pharm Prax. 1961;10:171-7
references.pmid: 14467205
references.citation: Int J Pharm. 2005 Sep 14;301(1-2):54-61
references.pmid: 16024191
references.citation: Eur J Pharm Biopharm. 2000 Mar;49(2):119-27
references.pmid: 10704894
references.citation: Drug Dev Ind Pharm. 2000 Nov;26(11):1177-83
references.pmid: 11068691
references.citation: Eur J Pharm Sci. 1999 Dec;9(2):131-6
references.pmid: 10620725